A detailed history of Rathbones Group PLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Rathbones Group PLC holds 30,400 shares of CNTA stock, worth $532,912. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,400
Previous 31,300 2.88%
Holding current value
$532,912
Previous $282,000 72.34%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$8.58 - $16.99 $7,722 - $15,290
-900 Reduced 2.88%
30,400 $486,000
Q3 2023

Nov 13, 2023

BUY
$6.01 - $8.24 $188,113 - $257,912
31,300 New
31,300 $202,000

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.65B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Rathbones Group PLC Portfolio

Follow Rathbones Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.